FIGURE 3.

High expression levels of AKR1C1 were observed in NSCLC clinical samples, particularly in metastatic tumors. (A) High mRNA fold change of AKR1C1 was observed among different cancer types in clinical samples, particularly in lung carcinoma. Data were obtained from the Oncomine database. https://www.oncomine.org. (B) AKR1C1 is upregulated in lung cancer samples compared with normal lung samples. The box plots of 486 lung cancer samples (red) and 338 normal samples (gray) revealed upregulation of AKR1C1 in lung cancer compared with normal tissue. Data were analyzed using the GEPIA database (http://gepia.cancer-pku.cn/); *p < 0.05. (C) Immunohistochemical staining showed that the expression levels of AKR1C1 were significantly upregulated in metastatic tumors compared with corresponding primary tumors obtained from the same NSCLC patient. (D) The effects of AKR1C1 on the overall survival of NSCLC patient. The data were analyzed by the Kaplan–Meier analysis. Lung Cancer. http://kmplot.com/analysis/index.php?p=service&cancer=lung.